In this R21 application we propose to assess cellular, molecular and immune correlates of efficacy and safety of nanoparticle formulations using a well characterized malaria vaccine candidate as a model immunogen. A vaccine based on Pfs25 protein targeting the sexual stages of the parasite provides a direct approach to reduce malaria transmission. In Plasmodium falciparum, Pfs230 and Pfs48/45 proteins produced within the intra-erythrocytic gametocyte stages and Pfs25, expressed during the mosquito stage development of zygote into ookinete, represent well established target antigens of transmission-blocking antibodies. Antibodies recognizing specific conformational epitopes in these proteins are potent blockers of infectivity of malaria parasites in the mosquito. We have recently succeeded in recombinant expression and purification of re-folded Pfs25, for the first time in near native conformation, in E. coli. The purified protein (rPfs25) in experimental adjuvants elicited strong immunogenicity in mice. Better and safer adjuvants and delivery methods need to be developed for eventual human applicability. Nanoparticles are fast gaining acceptability as safe and effective vaccine adjuvants. We propose to develop Pfs25 - nanoparticle formulations (Aim 1) and evaluate functional immune response in inbred and outbred mice (Aim 3). We also propose to study the immune response-related host gene expression changes at the site of vaccine injection to gain mechanistic insights of Pfs25-nanoparticle vaccine efficacy (Aim 2). Finally studies are also proposed to investigate relevant vaccine safety parameters (Aim 4). These studies will provide better understanding of cellular and molecular correlates of immunogenic efficacy and safety of nanoparticle formulations, and also provide the basis for more in depth studies on vaccine development, in general.

Public Health Relevance

Malaria parasites are responsible for nearly 300 million infections globally resulting in nearly a million deaths annually. Vaccines are urgently needed to control and eliminate the disease. The proposed research will focus on the development of a vaccine to stop transmission and help with the ultimate goal of malaria elimination.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
MO, Annie X Y
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Tulane University
Internal Medicine/Medicine
Schools of Public Health
New Orleans
United States
Zip Code
Heidari, Zahra; Arora, Jaspreet S; Datta, Dibyadyuti et al. (2017) Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes. Pharm Res 34:1796-1804
Datta, Dibyadyuti; Bansal, Geetha P; Grasperge, Brooke et al. (2017) Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques. Vaccine 35:7049-7056
Datta, Dibyadyuti; Bansal, Geetha P; Gerloff, Dietlind L et al. (2017) Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation. Vaccine 35:264-272
Juliano, Jonathan J; Parobek, Christian M; Brazeau, Nicholas F et al. (2016) Pooled Amplicon Deep Sequencing of Candidate Plasmodium falciparum Transmission-Blocking Vaccine Antigens. Am J Trop Med Hyg 94:143-6
Kumar, Rajesh; Ray, Paresh C; Datta, Dibyadyuti et al. (2015) Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Vaccine 33:5064-71
Kumar, Rajesh; Ledet, Grace; Graves, Richard et al. (2015) Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles. Pharm Res 32:3827-36
Datta, Dibyadyuti; Bansal, Geetha P; Kumar, Rajesh et al. (2015) Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by In Vivo Electroporation in Preclinical Studies in Mice. Clin Vaccine Immunol 22:1013-9
Lukianova-Hleb, Ekaterina; Bezek, Sarah; Szigeti, Reka et al. (2015) Transdermal Diagnosis of Malaria Using Vapor Nanobubbles. Emerg Infect Dis 21:1122-7
Kumar, Rajesh; Angov, Evelina; Kumar, Nirbhay (2014) Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding. Infect Immun 82:1453-9
Kumar, Rajesh; Nyakundi, Ruth; Kariuki, Thomas et al. (2013) Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons. Vaccine 31:3140-7